ArticleFrontiers in pharmacology2022

Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults.

Xiaohua Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.